News

Thalassemia case provides insight into history of malaria


 

Image by Peter H. Seeberger

Malaria-infected cell bursting

The earliest documented case of β-thalassemia in Sardinia suggests malaria was widespread on the island long before the Middle Ages, according to researchers.

The team noted that Sardinia has one of the highest incidence rates of β-thalassemia in Europe due to its long history of endemic malaria.

However, it has been assumed that malaria was only endemic on the island since the Middle Ages (500-1500 CE).

New research, published in the American Journal of Physical Anthropology, suggests malaria was probably already endemic on Sardinia during the Roman period.

Since ancient DNA of malaria is difficult to extract, the researchers studied thalassemia and other genetic adaptations in its place.

The team studied a thalassemia allele called cod39 β-thalassemia, which is dominant on Sardinia. They were able to confirm the presence of the cod39 allele in the 2000-year-old (approximately 300 BCE to 100 CE) remains of a Roman man.

“This is the very first documented case of the genetic adaptation to malaria on Sardinia,” said study author Claudia Vigano, of the Institute for Evolutionary Medicine of the University of Zurich in Switzerland.

“We also discovered that the person was genetically a Sardinian in all probability and not an immigrant from another area.”

“Our study shows the importance of a multidisciplinary approach to history,” said Abigail Bouwman, also of the Institute for Evolutionary Medicine of the University of Zurich.

“We are researching the evolution of today’s diseases, such as malaria, to explain why the human body becomes sick at all and how adaptations occur.”

Recommended Reading

Allele-matching in cord blood transplant yields better survival
MDedge Hematology and Oncology
Models provide new understanding of sickle cell disease
MDedge Hematology and Oncology
CRISPR sheds light on dyskeratosis congenita
MDedge Hematology and Oncology
Product granted fast track designation for aTTP
MDedge Hematology and Oncology
Predicting response to treatment in AML, MDS
MDedge Hematology and Oncology
Tests reveal risk of passing on SCD, other diseases
MDedge Hematology and Oncology
Predicting response to azacitidine in MDS
MDedge Hematology and Oncology
Mutations linked to Fanconi anemia
MDedge Hematology and Oncology
Studies support testing for iron deficiency in young women
MDedge Hematology and Oncology
Vaccine granted orphan designation for MDS
MDedge Hematology and Oncology